Literature DB >> 31228613

LMWH and its derivatives represent new rational for cancer therapy: construction strategies and combination therapy.

Shi Du1, Yao Yu1, Cheng Xu1, Hui Xiong1, Shan Yang1, Jing Yao2.   

Abstract

Low-molecular-weight heparin (LMWH) has attracted increasing attention as a tumor treatment because of its board range of physiological functions. Over the past decade, diverse LMWH derivatives have increased the variety of antitumor strategies available, serving not only as anti-tumor agents, but also as drug delivery platforms. In this review, we introduce the basic strategy for structural modification of LMWH to attenuate its antitumor activity while reducing its risk of bleeding and immune responses, as well as highlighting current applications of LMWH and its derivatives in cancer therapy. We select representative drug delivery systems involving LMWH derivatives and discuss the construction principles and therapeutic effects associated with their use. We also analyze progress made in the development of antitumor combination therapies, in which LMWH has shown synergistic or combined effects with other treatment strategies.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31228613     DOI: 10.1016/j.drudis.2019.06.011

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  6 in total

1.  Expression and characterization of heparinase II with MBP tag from a novel strain, Raoultella NX-TZ-3-15.

Authors:  Yinyin Li; Yue Lin; Yingzi Jiang; Hafiza Mahreen Mehwish; Muhammad Shahid Riaz Rajoka; Liqing Zhao
Journal:  Arch Microbiol       Date:  2022-08-11       Impact factor: 2.667

Review 2.  The Auxiliary Role of Heparin in Bone Regeneration and its Application in Bone Substitute Materials.

Authors:  Jing Wang; Lan Xiao; Weiqun Wang; Dingmei Zhang; Yaping Ma; Yi Zhang; Xin Wang
Journal:  Front Bioeng Biotechnol       Date:  2022-05-12

3.  Ursolic Acid Enhances the Sensitivity of MCF-7 and MDA-MB-231 Cells to Epirubicin by Modulating the Autophagy Pathway.

Authors:  Zhennan Wang; Pingping Zhang; Huan Jiang; Bing Sun; Huaizhi Luo; Aiqun Jia
Journal:  Molecules       Date:  2022-05-25       Impact factor: 4.927

Review 4.  Nanocarrier-Based Drug Delivery for Melanoma Therapeutics.

Authors:  Mingming Song; Chang Liu; Siyu Chen; Wenxiang Zhang
Journal:  Int J Mol Sci       Date:  2021-02-13       Impact factor: 5.923

Review 5.  Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules.

Authors:  Nipa Banik; Seong-Bin Yang; Tae-Bong Kang; Ji-Hong Lim; Jooho Park
Journal:  Int J Mol Sci       Date:  2021-09-29       Impact factor: 5.923

Review 6.  Dendrimer-Based Drug Delivery Systems for Brain Targeting.

Authors:  Yuefei Zhu; Chunying Liu; Zhiqing Pang
Journal:  Biomolecules       Date:  2019-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.